for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

G1 Therapeutics Inc

GTHX.OQ

Latest Trade

17.21USD

Change

-0.10(-0.58%)

Volume

107,050

Today's Range

16.96

 - 

17.58

52 Week Range

10.81

 - 

37.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.31
Open
17.40
Volume
107,050
3M AVG Volume
24.35
Today's High
17.58
Today's Low
16.96
52 Week High
37.00
52 Week Low
10.81
Shares Out (MIL)
42.07
Market Cap (MIL)
728.31
Forward P/E
-4.96
Dividend (Yield %)
--

Next Event

Q2 2021 G1 Therapeutics Inc Earnings Release

Latest Developments

More

G1 Therapeutics Receives Fast Track Designation From U.S. FDA For Cosela

G1 Therapeutics Reports Q1 Loss Per Share Of $0.65

G1 Therapeutics Reports Q4 Loss Per Share Of $0.67

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About G1 Therapeutics Inc

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Industry

Biotechnology & Drugs

Contact Info

700 Park Offices Drive, Suite 200

RESEARCH TRIANGLE PARK, NC

27709

United States

+1.919.2139835

http://www.g1therapeutics.com/

Executive Leadership

Garry A. Nicholson

Independent Chairman of the Board

John E. Bailey

President, Chief Executive Officer, Director

Jennifer K. Moses

Chief Financial Officer

Terry L. Murdock

Chief Operating Officer

Rajesh K. Malik

Chief Medical Officer, Senior Vice President - Research and Development

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.560

2019

-3.270

2020

-2.620

2021(E)

-3.491
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.24
Price To Book (MRQ)
2.96
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
12.19
LT Debt To Equity (MRQ)
12.19
Return on Investment (TTM)
-36.34
Return on Equity (TTM)
-33.51

Latest News

Latest News

BRIEF-G1 Therapeutics And Boehringer Ingelheim Announce Co-Promotion Agreement For Trilaciclib In Small Cell Lung Cancer In The U.S. And Puerto Rico

* G1 THERAPEUTICS AND BOEHRINGER INGELHEIM ANNOUNCE CO-PROMOTION AGREEMENT FOR TRILACICLIB IN SMALL CELL LUNG CANCER IN THE UNITED STATES AND PUERTO RICO

BRIEF-G1 Therapeutics And Genor Biopharma Announce Exclusive License Deal For Lerociclib In Asia-Pacific Region

* G1 THERAPEUTICS AND GENOR BIOPHARMA ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR LEROCICLIB IN ASIA-PACIFIC REGION

BRIEF-G1 Therapeutics Announces Flexible Credit Financing For Up To $100 Mln With Hercules Capital

* G1 THERAPEUTICS ANNOUNCES FLEXIBLE CREDIT FINANCING FOR UP TO $100 MILLION WITH HERCULES CAPITAL

BRIEF-G1 Therapeutics To Present Data Showing Myelopreservation Benefits Of Trilaciclib In Patients With Small Cell Lung Cancer

* G1 THERAPEUTICS TO PRESENT DATA SHOWING MYELOPRESERVATION BENEFITS OF TRILACICLIB IN PATIENTS WITH SMALL CELL LUNG CANCER AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM

BRIEF-G1 Therapeutics Announces Appointment Of New Board Member And Chief Commercial Officer

* G1 THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBER AND CHIEF COMMERCIAL OFFICER Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-G1 Therapeutics Says Rintodestrant Combination Trial With Palbociclib Expected To Initiate In Q2

* G1 THERAPEUTICS INC - RINTODESTRANT COMBINATION TRIAL WITH PALBOCICLIB EXPECTED TO INITIATE IN 2Q20

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up